For comparison, Cattaneo et al. reported an incidence of probable/proven and possible invasive fungal diseases (IFD) of 10.5% and 9.7%, respectively, in 114 patients with FLT-3 mutated AML treated with 3 + 7 + midostaurin. This evidence concerns the gene FLT3 and acute myeloid leukemia.